Sandbox Reserved 1645

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 34: Line 34:
Dominant mutations in the fibrillin-1 gene cause [https://www.omim.org/entry/154700?search=marfan%20syndrome&highlight=%28syndrome%7Csyndromic%29%20marfan Marfan syndrome (MFS)] and illustrate the physiological functions of elastic fibers. Most of the thousand known '''fibrillin-1''' mutations make the protein unstable and susceptible to proteolysis. Other point mutations interfere with folding. All patients are heterozygotes.
Dominant mutations in the fibrillin-1 gene cause [https://www.omim.org/entry/154700?search=marfan%20syndrome&highlight=%28syndrome%7Csyndromic%29%20marfan Marfan syndrome (MFS)] and illustrate the physiological functions of elastic fibers. Most of the thousand known '''fibrillin-1''' mutations make the protein unstable and susceptible to proteolysis. Other point mutations interfere with folding. All patients are heterozygotes.
-
Elastic fibers of patients with ''Marfan syndrome'' are poorly formed, accounting for most of the pathological changes. Most dangerously, weakness of elastic fibers in the aorta leads to an enlargement of the vessel, called an aneurysm, which is prone to rupture, with fatal consequences. Prophylactic replacement of the aorta with a synthetic graft and medical treatment with drugs that block adrenergic receptors allow patients a nearly normal life span. In some patients, a floppy mitral valve in the heart causes reflux of blood from the left ventricle back into the left atrium. Weak elastic fibers that suspend the lens of the eye result in dislocation of the lens and impaired vision. Weak elastic fibers result in lax joints and curvature of the spine. Most affected patients are tall, with long limbs and fingers, but the connection of these features to fibrillin is not known
+
Elastic fibers of patients with ''Marfan syndrome'' are poorly formed, accounting for most of the pathological changes. Most dangerously, weakness of elastic fibers in the aorta leads to an enlargement of the vessel, called an aneurysm, which is prone to rupture, with fatal consequences. Prophylactic replacement of the aorta with a synthetic graft and medical treatment with drugs that block adrenergic receptors allow patients a nearly normal life span. In some patients, a floppy mitral valve in the heart causes reflux of blood from the left ventricle back into the left atrium. Weak elastic fibers that suspend the lens of the eye result in dislocation of the lens and impaired vision. Weak elastic fibers result in lax joints and curvature of the spine. Most affected patients are tall, with long limbs and fingers, but the connection of these features to fibrillin is not known.
 +
<ref> D. Pollard, C.Earnshaw, J. Lippincott-Schwartz, G. T.Johson, Cell Biology, Third Edition.</ref>

Revision as of 15:35, 18 January 2022

This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Fibrillin-1

3D structure of fibrillin-1 (PDB ID : 2W86)

Drag the structure with the mouse to rotate

References

  1. Handford, P. A. (2000). Fibrillin-1, a calcium binding protein of extracellular matrix. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1498(2), 84–90. https://doi.org/10.1016/S0167-4889(00)00085-9
  2. Zhang H, Apfelroth SD, Hu W, Davis EC, Sanguineti C, Bonadio J, Mecham RP, Ramirez F (March 1994). "Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices". The Journal of Cell Biology. 124 (5): 855–63. doi:10.1083/jcb.124.5.855. PMC 2119952. PMID 8120105.
  3. Corson GM, Charbonneau NL, Keene DR, Sakai LY (March 2004). "Differential expression of fibrillin-3 adds to microfibril variety in human and avian, but not rodent, connective tissues". Genomics. 83 (3): 461–72. doi:10.1016/j.ygeno.2003.08.023. PMID 14962672.
  4. Gansner JM, Madsen EC, Mecham RP, Gitlin JD (October 2008). "Essential role for fibrillin-2 in zebrafish notochord and vascular morphogenesis". Developmental Dynamics. 237 (10): 2844–61. doi:10.1002/dvdy.21705. PMC 3081706. PMID 18816837.
  5. Sandra Schrenk Carola Cenzi Thomas Bertalot Maria Teresa Conconi Rosa Di Liddo, (2017), pages: 1213-1223,https://doi.org/10.3892/ijmm.2017.3343
  6. Weizmann Institute of Science, FBN1 gene, last consulted [09/01/22],https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBN1
  7. Robert N. Ono, Gerhard Sengle, Noe L. Charbonneau, Valerie Carlberg, Hans Peter Bächinger, Takako Sasaki, Sui Lee-Arteaga, Lior Zilberberg, Daniel B. Rifkin, Francesco Ramirez, Mon-LiChu, Lynn Y.Sakai. (2009). Latent Transforming Growth Factor β-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. Journal of Biological Chemistry, volume (284). https://www.sciencedirect.com/science/article/pii/S0021925818665056
  8. Shazia S. Chaudhry, Stuart A. Cain, Amanda Morgan, Sarah L. Dallas, C. Adrian Shuttleworth, Cay M. Kielty; Fibrillin-1 regulates the bioavailability of TGFβ1. J Cell Biol 29 January 2007; 176 (3): 355–367. doi: https://doi.org/10.1083/jcb.200608167
  9. Quondamatteo F, Reinhardt DP, Charbonneau NL, Pophal G, Sakai LY, Herken R (December 2002). "Fibrillin-1 and fibrillin-2 in human embryonic and early fetal development". Matrix Biology. 21 (8): 637–46. doi:10.1016/s0945-053x(02)00100-2. PMID 12524050. / Ammash NM, Sundt TM, Connolly HM (January 2008). "Marfan syndrome-diagnosis and management". Current Problems in Cardiology. 33 (1): 7–39. doi:10.1016/j.cpcardiol.2007.10.001. PMID 18155514. / Votteler M, Berrio DA, Horke A, Sabatier L, Reinhardt DP, Nsair A, Aikawa E, Schenke-Layland K (June 2013). "Elastogenesis at the onset of human cardiac valve development". Development. 140 (11): 2345–53. doi:10.1242/dev.093500. PMC 3912871. PMID 23637335.
  10. D. Pollard, C.Earnshaw, J. Lippincott-Schwartz, G. T.Johson, Cell Biology, Third Edition.
  11. E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. Molecular Syndormology, volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/
  12. TGFBR2.https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2
  13. Am J Hum Genet.(1999), Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288233/
Personal tools